

# Trevi Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference

NEW HAVEN, Conn., Nov. 9, 2021 /PRNewswire/ -- [Trevi Therapeutics, Inc.](#) (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that senior leadership members will participate in a virtual fireside chat, as well as host investor meetings, at the Stifel 2021 Virtual Healthcare Conference on November 15, 2021. Participants include Jennifer Good, President and CEO, Lisa Delfini, CFO, and Bill Forbes, CDO. Trevi's presentation is scheduled for 4 p.m. ET.

Senior leadership will participate in virtual fireside chat and host investor meetings at Stifel Healthcare Conference

A live webcast of the presentation can be accessed by visiting 'News & Events' in the 'Investors & News' section on the Company's website at [www.trevitherapeutics.com](http://www.trevitherapeutics.com). An archived replay of the webcast will also be available for 30 days on the Company's website following the conference.

## About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio to treat serious neurologically mediated conditions. Trevi is conducting a Phase 2b/3 clinical trial of Haduvio for the treatment of chronic pruritus associated with prurigo nodularis (PN) and a Phase 2 trial for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Trevi is also developing Haduvio for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.

Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.

## About Haduvio

Haduvio, an investigational therapy, is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed  $\kappa$ -opioid receptor agonist and  $\mu$ -opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The  $\kappa$ - and  $\mu$ -opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Nalbuphine's mechanism of action may also mitigate the risk of abuse associated with  $\mu$ -opioid agonists because it antagonizes, or blocks,  $\mu$ -opioid receptors. Parenteral nalbuphine is not currently classified as a controlled substance by the DEA in the United States and by regulatory authorities in most of Europe. Trevi intends to propose Haduvio as the trade name for nalbuphine ER. Haduvio is an investigational therapy that has been granted Fast Track designation by the FDA for the proposed indication of reduction of moderate to severe pruritus in patients with prurigo nodularis. Its safety and efficacy have not been evaluated by any regulatory authority.

## Investor Contact

Katie McManus  
Trevi Therapeutics, Inc.  
203-304-2499  
[k.mcmanus@trevitherapeutics.com](mailto:k.mcmanus@trevitherapeutics.com)

## Media Contact

Rosalia Scampoli  
914-815-1465  
[rscampoli@marketcompr.com](mailto:rscampoli@marketcompr.com)

SOURCE Trevi Therapeutics, Inc.

---

<https://ir.trevitherapeutics.com/2021-11-09-Trevi-Therapeutics-to-Present-at-Stifel-2021-Virtual-Healthcare-Conference>